Distinguished in Appendix Cancer

Dr. John L. Hays

Oncology
Osu Internal Medicine LLC
3651 Ridge Mill Dr, 
Hilliard, OH 
Accepting New Patients
Offers Telehealth
Distinguished in Appendix Cancer
Osu Internal Medicine LLC
3651 Ridge Mill Dr, 
Hilliard, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Hays is an Oncologist in Hilliard, Ohio. Dr. Hays is rated as a Distinguished provider by MediFind in the treatment of Appendix Cancer. His top areas of expertise are Colorectal Cancer, Ovarian Cancer, Appendix Cancer, and Familial Colorectal Cancer. Dr. Hays is currently accepting new patients.

His clinical research consists of co-authoring 69 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Appendix Cancer.

Specialties
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

OSU INTERNAL MEDICINE LLC
3651 Ridge Mill Dr, Hilliard, OH 43026
Other Locations
OSU INTERNAL MEDICINE LLC
2050 Kenny Rd, Columbus, OH 43221
OSU INTERNAL MEDICINE LLC
3900 Stoneridge Ln, Dublin, OH 43017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Sapanisertib
Study Phase: Phase 1
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer Indications
Enrollment Status: Completed
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drug: KPT-8602
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid Tumors
A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 10, 2025
Intervention Type: Drug, Other
Study Phase: Phase 1
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: August 23, 2024
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
Upifitamab Rilsodotin (Xmt-1536) An Open-Label, Multicenter, Dose Escalation And Expansion Study Of Upifitamab Rilsodotin In Combination With Carboplatin In Participants With High Grade Serous Ovarian Cancer (Upgrade-A)
Upifitamab Rilsodotin (Xmt-1536) An Open-Label, Multicenter, Dose Escalation And Expansion Study Of Upifitamab Rilsodotin In Combination With Carboplatin In Participants With High Grade Serous Ovarian Cancer (Upgrade-A)
Enrollment Status: Terminated
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drugs: XMT-1536 (Upifitamab Rilsodotin), Carboplatin
Study Phase: Phase 1
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations
Enrollment Status: Completed
Publish Date: February 09, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
Enrollment Status: Completed
Publish Date: February 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

69 Total Publications

Characterizing surveillance-associated anxiety following curative-intent surgery for gastrointestinal cancer: a mixed methods approach.
Characterizing surveillance-associated anxiety following curative-intent surgery for gastrointestinal cancer: a mixed methods approach.
Journal: Journal of cancer survivorship : research and practice
Published: March 07, 2025
Similar Doctors
Advanced in Appendix Cancer
Dr. Tarek M. Sabagh
Hematology Oncology | Hematology | Oncology
Advanced in Appendix Cancer
Dr. Tarek M. Sabagh
Hematology Oncology | Hematology | Oncology

Premier Health Specialists Inc

400 Sugar Camp Cir, Suite 200, 
Oakwood, OH 
 (60.6 miles away)
937-276-8320
Languages Spoken:
English, Arabic, Arabic - Jordanian, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Tarek Sabagh is a Hematologist Oncology specialist and a Hematologist in Oakwood, Ohio. Dr. Sabagh is rated as an Advanced provider by MediFind in the treatment of Appendix Cancer. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, Familial Pancreatic Cancer, and Bone Marrow Aspiration. Dr. Sabagh is currently accepting new patients.

Experienced in Appendix Cancer
Dr. Bhavana Konda
Oncology
Experienced in Appendix Cancer
Dr. Bhavana Konda
Oncology

Osu Internal Medicine LLC

3900 Stoneridge Ln, 
Dublin, OH 
 (4.8 miles away)
614-366-5001
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bhavana Konda is an Oncologist in Dublin, Ohio. Dr. Konda is rated as an Elite provider by MediFind in the treatment of Appendix Cancer. Her top areas of expertise are Neuroendocrine Tumor, Thyroid Cancer, Adrenal Cancer, Liver Embolization, and Pancreaticoduodenectomy. Dr. Konda is currently accepting new patients.

Advanced in Appendix Cancer
Dr. Daljeet J. Singh
Hematology Oncology | Hematology | Oncology
Advanced in Appendix Cancer
Dr. Daljeet J. Singh
Hematology Oncology | Hematology | Oncology

Mercy Health Physicians Springfield Specialty Care LLC

900 Scioto St, Suite 1, 
Urbana, OH 
 (33.1 miles away)
937-717-4884
Languages Spoken:
English, Punjabi, Spanish
See accepted insurances
Accepting New Patients

Daljeet Singh is a Hematologist Oncology specialist and a Hematologist in Urbana, Ohio. Dr. Singh is rated as an Advanced provider by MediFind in the treatment of Appendix Cancer. His top areas of expertise are Familial Colorectal Cancer, Small Lymphocytic Lymphoma (SLL), Breast Cancer, and Paget Disease of the Breast. Dr. Singh is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hays's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile